Combination therapy for treating cancer
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
1. A method for treatment of non-small cell lung cancer (NSCLC) comprising administering to a subject in need thereof:
(a) an amount of an EZH2 inhibitor, and
(b) an anaplastic lymphoma kinase (ALK) inhibitor.
2. The method of claim 1 , wherein the EZH2 inhibitor is tazemetostat or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the ALK inhibitor is one or more ALK inhibitors.
4. The method of claim 1 , wherein the ALK inhibitor is an inhibitor of ALK and ROS1, an inhibitor of ALK and EGFR, or a combination thereof.
5. The method of claim 1 , wherein the ALK inhibitor is ceritinib, crizotinib, or brigatinib, or a combination thereof.
6. The method of claim 1 , wherein the amount of the EZH2 inhibitor is between about 100 mg and about 1600 mg.
7. The method of claim 6 , wherein the amount of the EZH2 inhibitor is about 100 mg, about 200 mg, about 400 mg, about 800 mg, or about 1600 mg.
8. The method of claim 7 , wherein the amount of the EZH2 inhibitor is about 800 mg.
9. The method of claim 1 , wherein the EZH2 inhibitor is administered twice per day (BID).
10. The method of claim 1 , wherein the EZH2 inhibitor is administered orally.
11. The method of claim 1 , wherein the EZH2 inhibitor is administered as a capsule or tablet.
12. The method of claim 2 , wherein the amount of the EZH2 inhibitor is between about 100 mg and about 1600 mg.
13. The method of claim 12 , wherein the amount of the EZH2 inhibitor is about 100 mg, about 200 mg, about 400 mg, about 800 mg, or about 1600 mg.
14. The method of claim 13 , wherein the amount of the EZH2 inhibitor is about 800 mg.
15. The method of claim 2 , wherein the EZH2 inhibitor is administered twice per day (BID).
16. The method of claim 2 , wherein the EZH2 inhibitor is administered orally.
17. The method of claim 2 , wherein the EZH2 inhibitor is administered as a capsule or tablet.
18. The method of claim 5 , wherein the ALK inhibitor is ceritinib.